We are live on
!
Find out more
NMC
NEA Management Company Portfolio holdings
AUM
$1.76B
1-Year Est. Return
223.33%
This Fund
S&P 500
This Quarter
Est. Return
+14.5%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$1.76B
AUM Growth
-$202M
(-10%)
Cap. Flow
-$266M
Cap. Flow
% of AUM
-15.09%
Top 10 Holdings %
Top 10 Hldgs %
87.55%
Holding
28
New
1
Increased
2
Reduced
2
Closed
2
Top Buys
| 1 |
SGP
SpyGlass Pharma
SGP
|
+$199M |
| 2 |
ZBIO
Zenas BioPharma
ZBIO
|
+$11.2M |
| 3 |
Korro Bio
KRRO
|
+$2.28M |
Top Sells
| 1 |
Rhythm Pharmaceuticals
RYTM
|
+$311M |
| 2 |
Celcuity
CELC
|
+$136M |
| 3 |
Gossamer Bio
GOSS
|
+$26.9M |
| 4 |
SYBX
Synlogic
SYBX
|
+$3.27M |
Sector Composition
| 1 | Healthcare | 95.74% |
| 2 | Consumer Staples | 4.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ACLX
1
DELISTED
Arcellx
ACLX
| $350M | 19.88% |
3,045,262
| – | – |
|
|
2
Celcuity
CELC
$4.31B
| $261M | 14.83% |
2,285,561
-1,250,000
| -35% | -$136M |
|
|
SGP
3
SpyGlass Pharma
SGP
$661M
| $192M | 10.89% |
+7,392,301
| New | +$199M |
|
4
Trevi Therapeutics
TRVI
$2.71B
| $158M | 8.97% |
13,222,228
| – | – |
|
5
Savara
SVRA
$1.13B
| $134M | 7.6% |
24,471,264
| – | – |
|
6
Monte Rosa Therapeutics
GLUE
$2.07B
| $127M | 7.19% |
7,692,298
| – | – |
|
|
MBX
7
MBX Biosciences
MBX
$2.99B
| $108M | 6.13% |
3,614,486
| – | – |
|
|
ZBIO
8
Zenas BioPharma
ZBIO
$1.86B
| $78.7M | 4.47% |
4,023,219
+500,000
| +14% | +$11.2M |
|
9
Coursera
COUR
$1.59B
| $74.9M | 4.26% |
12,867,769
| – | – |
|
10
Aurinia Pharmaceuticals
AUPH
$2.05B
| $58.8M | 3.34% |
3,969,834
| – | – |
|
11
Oric Pharmaceuticals
ORIC
$1.11B
| $52.2M | 2.97% |
4,118,621
| – | – |
|
12
CRISPR Therapeutics
CRSP
$4.71B
| $50.4M | 2.86% |
1,058,570
| – | – |
|
13
Phathom Pharmaceuticals
PHAT
$873M
| $21.8M | 1.24% |
1,960,169
| – | – |
|
14
CVRx
CVRX
$130M
| $19.2M | 1.09% |
2,026,083
| – | – |
|
|
15
Korro Bio
KRRO
$177M
| $14.7M | 0.84% |
1,297,893
+207,100
| +19% | +$2.28M |
|
16
X4 Pharmaceuticals
XFOR
$360M
| $13.4M | 0.76% |
3,233,743
| – | – |
|
17
Champions Oncology
CSBR
$85.1M
| $9.85M | 0.56% |
1,713,720
| – | – |
|
18
Black Diamond Therapeutics
BDTX
$103M
| $9.48M | 0.54% |
4,448,757
| – | – |
|
|
IVA
19
Inventiva
IVA
$1.09B
| $8.03M | 0.46% |
1,462,586
| – | – |
|
20
Nkarta
NKTX
$186M
| $7.53M | 0.43% |
3,568,781
| – | – |
|
|
LONA
21
LeonaBio Inc
LONA
$67.8M
| $4.77M | 0.27% |
464,398
| – | – |
|
22
Senti Biosciences Holdings
SNTI
$13.6M
| $3.07M | 0.17% |
3,775,615
| – | – |
|
23
Marker Therapeutics
MRKR
$21.8M
| $2.11M | 0.12% |
1,625,678
| – | – |
|
|
OKUR
24
OnKure Therapeutics
OKUR
$170M
| $1.98M | 0.11% |
478,548
| – | – |
|
|
25
Gossamer Bio
GOSS
$83.2M
| $329K | 0.02% |
1,000,000
-17,093,034
| -94% | -$26.9M |
|
Similar funds
NM
EK
SLF
PCA
CCIA
SRIM
SW
CGH
NEA Management Company's Q1 2026 Portfolio in Review
As of Q1 2026, NEA Management Company held 28 positions worth $1.76B, down 10% from $1.96B the previous quarter. Its ten largest holdings account for 88% of the portfolio.
NEA Management Company withdrew a net $266M in Q1 2026, closing 2 positions and reducing 2 holdings. Its most notable exit was Rhythm Pharmaceuticals, an estimated $311M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Consumer Staples.
Against the trend, NEA Management Company opened a new position in SpyGlass Pharma worth $192M.
- NEA Management Company's largest Q1 2026 buy was SpyGlass Pharma: 7,392,301 shares worth $192M.
- NEA Management Company added most to Zenas BioPharma in Q1 2026, an estimated $11.2M increase.
- NEA Management Company's biggest Q1 2026 reduction was Celcuity, cutting an estimated $136M.
- NEA Management Company fully exited Rhythm Pharmaceuticals in Q1 2026, selling an estimated $311M.
- NEA Management Company's ten largest holdings make up 88% of its $1.76B portfolio in Q1 2026.
- NEA Management Company opened 1 new position and closed 2 in Q1 2026.
- NEA Management Company's portfolio value fell 10% quarter-over-quarter to $1.76B.
Based on NEA Management Company's 13F filing for Q1 2026, filed 15 May 2026.